April 16, 2012
Belgian pharmaceutical giant UCB Inc. on Thursday hit Covidien PLC subsidiary Mallinckrodt Inc. with a patent infringement suit over the rival drugmaker's plan to sell a generic version of Ritalin, UCB's attention deficit and hyperactivity disorder treatment.